Dana-Farber Cancer Institute
@danafarber.bsky.social
A leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | http://dana-farber.org
Appts: 877-442-3324 | http://dana-farber.org
Every year, physician researchers at Dana-Farber reveal new treatments, protocols, and outcomes that advance cancer research. Here are three of the most exciting — several nearing FDA approval. Read more: bit.ly/48uatxg
Three Recent Dana-Farber Research Studies to Know About
Published: November 5, 2025Written by: Maddi LangweilEvery year, physician researchers at Dana-Farber Cancer Institute reveal new treatments, protocols, and outcomes that advance cancer research. At one of this year’s biggest cancer research conferences, the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, Dana-Farber researchers presented 22 studies in breast, lung, and bladder cancer. Here are three of the most exciting advancements — several nearing U.S. Food and Drug Administration (FDA) approval — shared by our experts nearly 4,000 miles across the world. An ... Read more
bit.ly
December 30, 2025 at 1:30 PM
Every year, physician researchers at Dana-Farber reveal new treatments, protocols, and outcomes that advance cancer research. Here are three of the most exciting — several nearing FDA approval. Read more: bit.ly/48uatxg
Reposted by Dana-Farber Cancer Institute
“It feels really fulfilling and affirming, and it truly is an honor,” @danafarber.bsky.social’s Alexandria Monteiro tells @boston25news.com while donating her stem cells at the Kraft Family Blood Donor Center during the holidays to a pediatric patient needing a transplant.
➡️ bit.ly/49fDX0X
➡️ bit.ly/49fDX0X
Dana Farber employees donate life-saving stem cells to patient
Boston 25 Weather Brian Walshe Murder Trial(Opens in new window) The Local Life(Opens in new window) Share your pics(Opens in new window)
bit.ly
December 29, 2025 at 9:45 PM
“It feels really fulfilling and affirming, and it truly is an honor,” @danafarber.bsky.social’s Alexandria Monteiro tells @boston25news.com while donating her stem cells at the Kraft Family Blood Donor Center during the holidays to a pediatric patient needing a transplant.
➡️ bit.ly/49fDX0X
➡️ bit.ly/49fDX0X
“Now, for the first time ever, we’ve created a molecularly based stratification biomarker,” says pediatric oncologist Brian Crompton, MD.
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
Published: November 20, 2025Written by: Beth DoughertyKey Takeaways: Molecular biomarkers have been used for more than two decades to guide cancer treatment and have transformed outcomes in many forms of cancer. For rare cancers like Ewing sarcoma, discovering clinically viable biomarkers has been a challenge — until recent research by Dana-Farber scientists. In 2014, Dana-Farber pediatric ... Read more
bit.ly
December 29, 2025 at 9:25 PM
“Now, for the first time ever, we’ve created a molecularly based stratification biomarker,” says pediatric oncologist Brian Crompton, MD.
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
We’re proud to be included in Becker’s Great Hospitals in America list, which recognizes organizations that stand out for exceptional clinical performance, unwavering focus on patient safety, and dedication to innovation, research and education. View the full list here: bit.ly/49nr2Lv
December 27, 2025 at 1:30 PM
We’re proud to be included in Becker’s Great Hospitals in America list, which recognizes organizations that stand out for exceptional clinical performance, unwavering focus on patient safety, and dedication to innovation, research and education. View the full list here: bit.ly/49nr2Lv
The COMET study led by Ann Partridge, MD, MPH, and colleagues was recognized by @jama.com as part of their "Research of the Year” roundup. Results of COMET results suggest that active monitoring could be a reasonable approach to management of low-risk DCIS. Learn more: bit.ly/492IwLS
December 24, 2025 at 1:35 PM
The COMET study led by Ann Partridge, MD, MPH, and colleagues was recognized by @jama.com as part of their "Research of the Year” roundup. Results of COMET results suggest that active monitoring could be a reasonable approach to management of low-risk DCIS. Learn more: bit.ly/492IwLS
The FDA has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. The approval is based on results from the phase III DESTINY-Breast09 study, led by Sara Tolaney, MD, Chief of Breast Oncology.
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer | Dana-Farber Cancer Institute
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
bit.ly
December 23, 2025 at 2:39 PM
The FDA has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. The approval is based on results from the phase III DESTINY-Breast09 study, led by Sara Tolaney, MD, Chief of Breast Oncology.
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports. The +1 scores reflect that both programs outperformed the expected one-year survival rate for allogeneic (donor) stem cell transplants in the United States.
bit.ly
December 22, 2025 at 9:39 PM
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.
Reposted by Dana-Farber Cancer Institute
ICYMI: Breast cancer research breakthroughs discussed at #ESMO25 by @danafarber.bsky.social's Breast Oncology Center. Learn how these discoveries will impact clinical care going forward: 🎥 bit.ly/4j4fa4x
Breast Cancer Breakthroughs: ESMO25 Highlights
Share your videos with friends, family, and the world
bit.ly
December 22, 2025 at 8:45 PM
ICYMI: Breast cancer research breakthroughs discussed at #ESMO25 by @danafarber.bsky.social's Breast Oncology Center. Learn how these discoveries will impact clinical care going forward: 🎥 bit.ly/4j4fa4x
Meet Evan Chen, MD, a medical oncologist who treats patients with acute leukemias and myeloid malignancies. Learn more about his clinic research, which focuses on the development of cellular therapies for leukemias and translational studies of leukemia epigenetics: bit.ly/48ZI6rp
December 16, 2025 at 1:00 PM
Meet Evan Chen, MD, a medical oncologist who treats patients with acute leukemias and myeloid malignancies. Learn more about his clinic research, which focuses on the development of cellular therapies for leukemias and translational studies of leukemia epigenetics: bit.ly/48ZI6rp
Reposted by Dana-Farber Cancer Institute
"This gift keeps reinforcing to me the beauty in the world,” @danafarber.bsky.social oncology nurse navigator Idalina Colburn tells @wbztv.bsky.social’s Anna Meiler after Good News Movement surprised her with a trip from Expedia so her family may continue making happy memories.
➡️ bit.ly/4oUGbIX
➡️ bit.ly/4oUGbIX
Dana-Farber nurse battling cancer surprised with free vacation for family
Idalina Colburn does not let her cancer diagnosis hold her back from treating patients at Dana-Farber Cancer Institute. Her story got the attention of a group that wanted to make a difference. WBZ-TV’s Anna Meiler reports.
bit.ly
December 14, 2025 at 4:30 PM
"This gift keeps reinforcing to me the beauty in the world,” @danafarber.bsky.social oncology nurse navigator Idalina Colburn tells @wbztv.bsky.social’s Anna Meiler after Good News Movement surprised her with a trip from Expedia so her family may continue making happy memories.
➡️ bit.ly/4oUGbIX
➡️ bit.ly/4oUGbIX
Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty.
December 15, 2025 at 2:30 PM
Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty.
Melissa Levin, MSW, LICSW, recently talked with @ascopost.bsky.social about our Neuro-Inclusive Oncology Care and Empowerment Program. Learn more: bit.ly/4rPKRCJ
Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities
A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden on...
bit.ly
December 14, 2025 at 1:30 PM
Melissa Levin, MSW, LICSW, recently talked with @ascopost.bsky.social about our Neuro-Inclusive Oncology Care and Empowerment Program. Learn more: bit.ly/4rPKRCJ
We’re proud to be included in @forbes.com’s Top 2025 Charities list! Thank you for your continued support and generosity as we advance our momentum of discovery to improve cancer care and expand access in our community and for patients around the world.
View the full list: bit.ly/4rS4E47
View the full list: bit.ly/4rS4E47
Forbes Top Charities 2025 List - Rankings of Best Charities to Donate To
Forbes’ America’s Top Charities 2025 list ranks the 100 biggest charities in the U.S. based on private contributions received, and offers key financial metrics to guide donor giving.
bit.ly
December 13, 2025 at 1:00 PM
We’re proud to be included in @forbes.com’s Top 2025 Charities list! Thank you for your continued support and generosity as we advance our momentum of discovery to improve cancer care and expand access in our community and for patients around the world.
View the full list: bit.ly/4rS4E47
View the full list: bit.ly/4rS4E47
Congratulations to @stolaney1.bsky.social on receiving @theaacr.bsky.social's Outstanding Investigator Award for Breast Cancer Research. As part of this recognition, she will present her lecture “Lessons Learned: A Journey Towards Treatment Personalization” tomorrow at #SABCS25. ➡️ bit.ly/3KouH2i
Sara Tolaney Honored With AACR’s Outstanding Investigator Award for Breast Cancer Research | Dana-Farber Cancer Institute
Dr. Sara M. Tolaney is the recipient of the 2025 AACR Outstanding Investigator Award for Breast Cancer Research, supported by the Breast Cancer Research Foundation.
bit.ly
December 11, 2025 at 5:00 PM
Congratulations to @stolaney1.bsky.social on receiving @theaacr.bsky.social's Outstanding Investigator Award for Breast Cancer Research. As part of this recognition, she will present her lecture “Lessons Learned: A Journey Towards Treatment Personalization” tomorrow at #SABCS25. ➡️ bit.ly/3KouH2i
Congratulations to Nolan Priedigkeit, MD, PhD, on receiving the 2025 @sabcs.bsky.social Rising Star Award, which recognizes early career scientists and clinicians conducting impactful research in the field of breast cancer.
December 10, 2025 at 10:30 PM
Congratulations to Nolan Priedigkeit, MD, PhD, on receiving the 2025 @sabcs.bsky.social Rising Star Award, which recognizes early career scientists and clinicians conducting impactful research in the field of breast cancer.
Improvements in immunotherapy are leading to favorable results and reduced toxicities in treating patients with acute lymphoblastic leukemia. Get up to speed on the latest with Marlise R. Luskin, MD, MSCE: bit.ly/3JhTFQo
December 9, 2025 at 8:00 PM
Improvements in immunotherapy are leading to favorable results and reduced toxicities in treating patients with acute lymphoblastic leukemia. Get up to speed on the latest with Marlise R. Luskin, MD, MSCE: bit.ly/3JhTFQo
We're proud to showcase our contributions to breast cancer research at #SABCS25. For highlights, schedules, and more, visit us at bit.ly/3Y3DGJe.
San Antonio Breast Cancer Symposium 2025 - Dana-Farber
Many Dana-Farber clinician scientists are participating in the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9-12 in San Antonio Texas.
physicianresources.dana-farber.org
December 9, 2025 at 1:00 PM
We're proud to showcase our contributions to breast cancer research at #SABCS25. For highlights, schedules, and more, visit us at bit.ly/3Y3DGJe.
Johann-Christoph Jann, MD, presents new research on the activation of endogenous retroviral elements that may drive inflammation and cellular transformation in STAG2-mutant myeloid malignancies. @tothovalab.bsky.social #ASH25
December 8, 2025 at 10:04 PM
Johann-Christoph Jann, MD, presents new research on the activation of endogenous retroviral elements that may drive inflammation and cellular transformation in STAG2-mutant myeloid malignancies. @tothovalab.bsky.social #ASH25
We’re back today at #ASH25. Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in blood cancer care and research or join us at our upcoming discussions and poster presentations: bit.ly/3LYDHeL
December 8, 2025 at 2:23 PM
We’re back today at #ASH25. Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in blood cancer care and research or join us at our upcoming discussions and poster presentations: bit.ly/3LYDHeL
The second day of poster presentations at #ASH25 featured research ranging from venetoclax and pirtobrutinib in relapsed/refractory Waldenström's macroglobulinemia to spatial proteomics of the bone marrow.
December 7, 2025 at 11:53 PM
The second day of poster presentations at #ASH25 featured research ranging from venetoclax and pirtobrutinib in relapsed/refractory Waldenström's macroglobulinemia to spatial proteomics of the bone marrow.
Andrew Lane, MD, PhD, shares an update on TAG-AZA-VEN for BPDCN.
“These early results point to a safer, more workable option that can keep patients on track, often toward transplant, while addressing co-existing disease.” #ASH25
“These early results point to a safer, more workable option that can keep patients on track, often toward transplant, while addressing co-existing disease.” #ASH25
December 7, 2025 at 10:31 PM
Andrew Lane, MD, PhD, shares an update on TAG-AZA-VEN for BPDCN.
“These early results point to a safer, more workable option that can keep patients on track, often toward transplant, while addressing co-existing disease.” #ASH25
“These early results point to a safer, more workable option that can keep patients on track, often toward transplant, while addressing co-existing disease.” #ASH25
Austin Kim, MD, presents results from the phase 1/2 MAVO study evaluating acalabrutinib + venetoclax + obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma.
#ASH25
#ASH25
December 7, 2025 at 10:18 PM
Austin Kim, MD, presents results from the phase 1/2 MAVO study evaluating acalabrutinib + venetoclax + obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma.
#ASH25
#ASH25
Jennifer Brown, MD, PhD, reports on insights from the ALPINE trial on symptom-based progression-free survival (S-PFS) as a patient-centric endpoint in CLL/SLL. The approach helps differentiate treatments and strengthens patient-focused evaluation in future trials. #ASH25
December 7, 2025 at 9:59 PM
Jennifer Brown, MD, PhD, reports on insights from the ALPINE trial on symptom-based progression-free survival (S-PFS) as a patient-centric endpoint in CLL/SLL. The approach helps differentiate treatments and strengthens patient-focused evaluation in future trials. #ASH25
Shayna Sarosiek, MD, reports new data from the WM-NET1 trial evaluating loncastuximab tesirine in relapsed/refractory Waldenström macroglobulinemia, including high-risk patients with CXCR4 or TP53 mutations — a group known to have more therapy-resistant disease and shorter response durations. #ASH25
December 7, 2025 at 6:14 PM
Shayna Sarosiek, MD, reports new data from the WM-NET1 trial evaluating loncastuximab tesirine in relapsed/refractory Waldenström macroglobulinemia, including high-risk patients with CXCR4 or TP53 mutations — a group known to have more therapy-resistant disease and shorter response durations. #ASH25